RCM
MCRB icon

RA Capital Management’s Seres Therapeutics MCRB Stock Holding History

RA Capital Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-255,277
Closed -$1.9M – 102
2021
Q2 		$1.9M Buy
255,277
+70,567
+38% +$29.8M 0.03% 91
2021
Q1 		$76.1M Buy
+184,710
New +$85.1M 1.15% 26
2020
Q4 		– Sell
-237,500
Closed -$134M – 85
2020
Q3 		$134M Buy
+237,500
New +$79M 2.46% 9
2015
Q4 		– Sell
-12,332
Closed -$7.31M – 42
2015
Q3 		$7.31M Hold
12,332
– – 1.05% 31
2015
Q2 		$10.2M Buy
+12,332
New +$10.8M 1.03% 29

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RA Capital Management's MCRB Position: Q3 2021 in Review

RA Capital Management sold out of Seres Therapeutics (MCRB) in Q3 2021, closing a stake of 255,277 shares — an estimated $1.9M sold.

RA Capital Management first reported a position in MCRB in Q2 2015 and held it in 5 quarters. The position peaked at $134M in Q3 2020. 133 funds tracked by Wall St. Rank hold MCRB as of Q3 2021.

  • RA Capital Management reported no remaining Seres Therapeutics position as of Q3 2021 after selling out during the quarter.
  • RA Capital Management sold 255,277 Seres Therapeutics shares in Q3 2021, an estimated $1.9M.
  • RA Capital Management first reported a position in Seres Therapeutics in Q2 2015 and held it in 5 quarters.
  • RA Capital Management's Seres Therapeutics position peaked at $134M in Q3 2020.
  • 133 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2021.

Based on RA Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.